Rapid Micro Biosystems Beheer

Beheer criteriumcontroles 3/4

De CEO Rapid Micro Biosystems is Rob Spignesi, benoemd in Oct2014, heeft een ambtstermijn van 10.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.80M, bestaande uit 34.3% salaris en 65.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.75% van de aandelen van het bedrijf, ter waarde $ 347.36K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.8 jaar en 6.1 jaar.

Belangrijke informatie

Rob Spignesi

Algemeen directeur

US$1.8m

Totale compensatie

Percentage CEO-salaris	34.3%
Dienstverband CEO	10.1yrs
Eigendom CEO	0.7%
Management gemiddelde ambtstermijn	3.8yrs
Gemiddelde ambtstermijn bestuur	6.1yrs

Recente managementupdates

Recent updates

Rapid Micro Biosystems, Inc.'s (NASDAQ:RPID) Shares Leap 25% Yet They're Still Not Telling The Full Story

Nov 02

Is Rapid Micro Biosystems (NASDAQ:RPID) In A Good Position To Invest In Growth?

Oct 29

A Piece Of The Puzzle Missing From Rapid Micro Biosystems, Inc.'s (NASDAQ:RPID) 32% Share Price Climb

Aug 03

We're Keeping An Eye On Rapid Micro Biosystems' (NASDAQ:RPID) Cash Burn Rate

Jun 30

Rapid Micro to introduce RMBNucleus software for mold detection in pharma manufacturing

Oct 10

Companies Like Rapid Micro Biosystems (NASDAQ:RPID) Are In A Position To Invest In Growth

May 09

Earnings Release: Here's Why Analysts Cut Their Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Price Target To US$17.67

Mar 08

We're Not Very Worried About Rapid Micro Biosystems' (NASDAQ:RPID) Cash Burn Rate

Feb 07

Analyse CEO-vergoeding

Hoe is Rob Spignesi's beloning veranderd ten opzichte van Rapid Micro Biosystems's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$48m
Jun 30 2024	n/a	n/a	-US$50m
Mar 31 2024	n/a	n/a	-US$52m
Dec 31 2023	US$2m	US$617k	-US$52m
Sep 30 2023	n/a	n/a	-US$58m
Jun 30 2023	n/a	n/a	-US$61m
Mar 31 2023	n/a	n/a	-US$60m
Dec 31 2022	US$2m	US$593k	-US$61m
Sep 30 2022	n/a	n/a	-US$59m
Jun 30 2022	n/a	n/a	-US$68m
Mar 31 2022	n/a	n/a	-US$69m
Dec 31 2021	US$1m	US$507k	-US$78m
Sep 30 2021	n/a	n/a	-US$77m
Jun 30 2021	n/a	n/a	-US$63m
Mar 31 2021	n/a	n/a	-US$60m
Dec 31 2020	US$1m	US$445k	-US$45m

Compensatie versus markt: De totale vergoeding ($USD 1.80M ) Rob } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 652.28K ).

Compensatie versus inkomsten: De vergoeding van Rob is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Rob Spignesi (54 yo)

10.1yrs

Tenure

US$1,797,254

Compensatie

Mr. Robert G. Spignesi Jr., also known as Rob, has been Chief Executive Officer, President and Director of Rapid Micro Biosystems, Inc. since October 2014. Mr. Spignesi is employed at SGG Partners, LLC. He...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Robert Spignesi	CEO, President & Director	10.1yrs	US$1.80m	0.75% $ 347.4k
Sean Wirtjes	Chief Financial Officer	6.2yrs	US$923.84k	0.54% $ 250.0k
John J. Wilson	Chief Operating Officer	3.8yrs	US$957.95k	0.19% $ 89.9k
Michael Beaulieu	Vice President of Investor Relations & Corporate Communications	no data	geen gegevens	geen gegevens
James Xu	VP of Legal & Secretary	no data	geen gegevens	geen gegevens
Michael Wysocki	Senior Vice President of Sales & Marketing	1.5yrs	geen gegevens	geen gegevens
Kristine Williams	Senior Vice President of Product	1.6yrs	geen gegevens	geen gegevens

3.8yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van RPID wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Robert Spignesi	CEO, President & Director	10.1yrs	US$1.80m	0.75% $ 347.4k
Natale Ricciardi	Independent Director	8.7yrs	US$70.08k	0% $ 0
Richard Kollender	Independent Director	6.1yrs	US$65.25k	0.19% $ 89.0k
Kirk Malloy	Independent Chairman of Board	1.3yrs	US$71.01k	0.12% $ 54.0k
Jeffrey Schwartz	Independent Director	6.6yrs	US$88.97k	19.65% $ 9.1m
Melinda Litherland	Independent Director	3.4yrs	US$70.25k	0% $ 0
Inese Lowenstein	Independent Director	2.9yrs	US$82.40k	0.023% $ 10.8k

6.1yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van RPID wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.1 jaar).

Rapid Micro Biosystems Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Independent Director recently bought US$50k worth of stock

Rapid Micro Biosystems, Inc., Annual General Meeting, May 23, 2024

Rapid Micro Biosystems, Inc. Appoints of Kirk Malloy as Chair of Its Board of Directors

Rapid Micro Biosystems, Inc., Annual General Meeting, May 23, 2022

Alexander Schmitz Not to Stand for Reelection as Member of the Board of Directors of Rapid Micro Biosystems, Inc

Insider recently bought US$70k worth of stock

Recent updates

New major risk - Revenue and earnings growth

Rapid Micro Biosystems, Inc.'s (NASDAQ:RPID) Shares Leap 25% Yet They're Still Not Telling The Full Story

Rapid Micro Biosystems, Inc. Re-Affirms Revenue Guidance for the Full Year 2024

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Rapid Micro Biosystems (NASDAQ:RPID) In A Good Position To Invest In Growth?

Rapid Micro Biosystems, Inc. to Report Q3, 2024 Results on Nov 01, 2024

Independent Director recently bought US$50k worth of stock

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

A Piece Of The Puzzle Missing From Rapid Micro Biosystems, Inc.'s (NASDAQ:RPID) 32% Share Price Climb

Rapid Micro Biosystems, Inc. to Report Q2, 2024 Results on Aug 02, 2024

We're Keeping An Eye On Rapid Micro Biosystems' (NASDAQ:RPID) Cash Burn Rate

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Rapid Micro Biosystems, Inc. to Report Q1, 2024 Results on May 03, 2024

Rapid Micro Biosystems, Inc., Annual General Meeting, May 23, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Rapid Micro Biosystems, Inc. Provides Revenue Guidance for the Full Year 2024

Rapid Micro Biosystems, Inc. to Report Fiscal Year 2023 Results on Mar 01, 2024

Rapid Micro Biosystems, Inc. Receives A Non-Compliance Notification Letter from the Nasdaq

Rapid Micro Biosystems Announces the Upcoming Availability of Rapid Sterility Application for the Growth Direct® System

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Rapid Micro Biosystems, Inc. Reaffirms Revenue Guidance for the Fiscal Year 2023

Rapid Micro Biosystems, Inc. to Report Q3, 2023 Results on Nov 03, 2023

Rapid Micro Biosystems Receives a Notification Letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rapid Micro Biosystems, Inc. to Report Q2, 2023 Results on Aug 04, 2023

Rapid Micro Biosystems, Inc. Appoints of Kirk Malloy as Chair of Its Board of Directors

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rapid Micro Biosystems, Inc. Reaffirms Revenue Guidance for the Full Year of 2023

Consensus revenue estimates fall by 11%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Rapid Micro Biosystems, Inc. to Report Q4, 2022 Results on Mar 03, 2023

Rapid Micro Biosystems, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter and Full Year of 2022

Rapid Micro Biosystems, Inc. Announces Publication of Multi-Author Case Study Supporting Fully Automated Colony Counting in Pharmaceutical Microbiology

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$9.00

Third quarter 2022 earnings released: US$0.38 loss per share (vs US$0.71 loss in 3Q 2021)

Rapid Micro Biosystems, Inc. Reaffirms Full Year 2022 Revenue Outlook

Rapid Micro Biosystems, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Rapid Micro Biosystems, Inc. Announces RMBnucleus Mold Alarm for the Growth Direct System

Rapid Micro to introduce RMBNucleus software for mold detection in pharma manufacturing

Kennedy Lewis Capital Partners Master Fund II LP and Kennedy Lewis Capital Partners Master Fund III LP managed by Kennedy Lewis Investment Management LLC cancelled the acquisition of remaining 85.67% stake in Rapid Micro Biosystems, Inc. (NasdaqGS:RPID).

Rapid Micro Biosystems, Inc. Revises Earnings Guidance for the Full Year 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Rapid Micro Biosystems, Inc. to Report Q2, 2022 Results on Aug 12, 2022

Kennedy Lewis Investment Management LLC delivered a Non-Binding Proposal to acquire remaining 85.67% stake in Rapid Micro Biosystems, Inc. (NasdaqGS:RPID) for approximately $160 million.

Rapid Micro Biosystems, Inc.(NasdaqGS:RPID) dropped from Russell 2500 Value Index

Rapid Micro Biosystems, Inc. Reaffirms Earnings Guidance For Full Year 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Companies Like Rapid Micro Biosystems (NASDAQ:RPID) Are In A Position To Invest In Growth

Rapid Micro Biosystems, Inc., Annual General Meeting, May 23, 2022

Alexander Schmitz Not to Stand for Reelection as Member of the Board of Directors of Rapid Micro Biosystems, Inc

Insider recently bought US$70k worth of stock

Earnings Release: Here's Why Analysts Cut Their Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Price Target To US$17.67

Rapid Micro Biosystems, Inc. Reaffirms Revenue Guidance Full Year 2022

Full year 2021 earnings: Revenues in line with analyst expectations

Rapid Micro Biosystems, Inc. to Report Q4, 2021 Results on Mar 04, 2022

We're Not Very Worried About Rapid Micro Biosystems' (NASDAQ:RPID) Cash Burn Rate

Rapid Micro Biosystems Provides Revenue Guidance for the Full Year 2022

Third quarter 2021 earnings released: US$0.71 loss per share

Rapid Micro Biosystems, Inc. Provides Revenue Guidance for the Full Year of 2021

Rapid Micro Biosystems, Inc. has completed an IPO in the amount of $158.4 million.

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden